Search
Ferric derisomaltose
go.drugbank.com/drugs/DB15617ApprovedInvestigationalThe latter is an iron carbohydrate oligosaccharide that works to release iron. Ferric derisomaltose was developed by Pharmacosmos Therapeutics ad was granted FDA approval in January 2020. … Iron deficiency is an extremely common condition and is the most frequent cause of anemia worldwide.
Products: Monofer 100 mg/ml solution for injection/infusion in vials, Monofer 100mg/ml solution for injection/infusion in ampoulesAlanosine
go.drugbank.com/drugs/DB05540InvestigationalAn amino acid analogue and antibiotic derived from the bacterium Streptomyces alanosinicus with antimetabolite and potential antineoplastic activities.
Categories: Compounds used in a research, industrial, or household settingIberdomide
go.drugbank.com/drugs/DB12101Investigational[L64055] It binds cereblon, the substrate-recognition component of an E3 ubiquitin ligase complex, and drives the ubiquitination and proteasomal degradation of the transcription factors Aiolos and Ikaros … [L64055,L64056] It is the first cereblon E3 ligase modulator (CELMoD) approved for multiple myeloma.[L64057]
Categories: Cereblon E3 ligase modulatorVilanterol
go.drugbank.com/drugs/DB09082ApprovedInvestigational[L46481,L44461,L44456] BREO ELLIPTA is the first vilanterol-containing product to be approved by the FDA in May 2013, followed by ANORO ELLIPTA in December 2013 and TRELEGY ELLIPTA in September 2020. … Increases in cyclic AMP are associated with the relaxation of bronchial smooth muscle and inhibition of the release of hypersensitivity mediators from mast cells in the lungs.
Vorasidenib
go.drugbank.com/drugs/DB17097ApprovedInvestigationalVorasidenib is a first-in-class dual isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor. … [A264209] It works by suppressing the levels of D-2-hydroxyglutarate (2-HG), an oncometabolite produced by mutant IDH1 and IDH2 isoforms.
Nylidrin
go.drugbank.com/drugs/DB06152ApprovedWithdrawnFDA has considered nylidrin as "lacking substantial evidence of effectiveness" in cerebral ischemia, cerebral arteriosclerosis, and other cerebral circulatory insufficiencies. … Some studies show the evidence of improving cognitive impairment in selected individuals, such as geriatric patients with mild to moderate symptoms of cognitive, emotional and physical impairment [L2279
L-tartaric acid
go.drugbank.com/drugs/DB09459ApprovedTartaric acid is a white crystalline organic acid that occurs naturally in many plants, most notably in grapes.Tartaric is an alpha-hydroxy-carboxylic acid, is diprotic and aldaric in acid characteristics
Mixtures: E-Z-gas 2 GranulesDesmopressin
go.drugbank.com/drugs/DB00035ApprovedInvestigationalDesmopressin is primarily indicated for the treatment of central diabetes insipidus, primary nocturnal enuresis (bedwetting) in children, and nocturia in adults [A275458, L56104]. … On January 15, 2026, the FDA approved a new low-dose sublingual film formulation specifically for the treatment of nocturia in patients at high risk for fluid overload, utilizing a specialized delivery
Karaya gum
go.drugbank.com/drugs/DB10535ApprovedKaraya gum allergenic extract is used in allergenic testing.
Categories: Compounds used in a research, industrial, or household settingNedosiran
go.drugbank.com/drugs/DB17635ApprovedInvestigational[A261685] Nedosiran was approved by the FDA on October 2<sup>nd</sup>, 2023, under the brand name RIVFLOZA to lower urinary oxalate levels in children 9 years of age and older and adults with primary … Nedosiran is an RNA interference targeting hepatic lactate dehydrogenase, the enzyme responsible for the conversion of glyoxylate to oxalate.